LEADER 01528nam 2200373 n 450 001 996384914803316 005 20200824120723.0 035 $a(CKB)4940000000066439 035 $a(EEBO)2240874424 035 $a(UnM)ocm99883652e 035 $a(UnM)99883652 035 $a(EXLCZ)994940000000066439 100 $a19940803d1648 uh 101 0 $aeng 135 $aurbn||||a|bb| 200 13$aAn ordinance of the Lords and Commons assembled in Parliament$b[electronic resource] $eenabling the committee of the county of Worcester, to raise 100. horse, and 300. foot, to suppresse all tumults in the said county, with power to assesse 100. l. per week, for the maintenance of those forces. 210 $aLondon $cprinted for John Wright, at the Kings Head in the Old-Bayley,$d1648. 215 $a1 sheet ([1] p.) 300 $aOrdered by the House of Lords to be printed and published. 300 $aReproduction of original in the British Library. 330 $aeebo-0018 606 $aBroadsides$zEngland$zLondon$vEarly works to 1800 607 $aGreat Britain$xHistory$yCivil War, 1642-1649$vEarly works to 1800 607 $aGreat Britain$xMilitia$vEarly works to 1800 607 $aWorcester (England)$xHistory$vEarly works to 1800 615 0$aBroadsides 801 0$bCu-RivES 801 1$bCu-RivES 801 2$bCStRLIN 801 2$bCu-RivES 906 $aBOOK 912 $a996384914803316 996 $aAn ordinance of the Lords and Commons assembled in Parliament$92298865 997 $aUNISA LEADER 01752oam 2200481 a 450 001 9910698454103321 005 20230902161909.0 035 $a(CKB)3460000000106931 035 $a(OCoLC)547500496$z(OCoLC)762291096$z(OCoLC)776023809 035 $a(EXLCZ)993460000000106931 100 $a20100308d2009 ua 0 101 0 $aeng 135 $aurbn||||m|||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCurrent issues in deposit insurance$b[electronic resource] $ehearing before the Subcommittee on Financial Institutions of the Committee on Banking, Housing, and Urban Affairs, United States Senate, One Hundred Eleventh Congress, first session, on strengthening deposit insurance and reviewing increasing the FDIC and NCUA's borrowing authority from Treasury, March 19, 2009 210 1$aWashington :$cU.S. G.P.O.,$d2009. 215 $a1 online resource (iii, 55 pages) 225 1 $aS. hrg. ;$v111-159 300 $aTitle from PDF title screen (viewed on Mar. 8, 2010). 300 $aPaper version available for sale by the Supt. of Docs., U.S. G.P.O. 320 $aIncludes bibliographical references. 517 $aCurrent issues in deposit insurance 606 $aDeposit insurance$zUnited States 606 $aDeposit insurance$2fast 607 $aUnited States$2fast 615 0$aDeposit insurance 615 7$aDeposit insurance. 801 0$bGPO 801 1$bGPO 801 2$bUBY 801 2$bOCLCQ 801 2$bGPO 801 2$bOCLCE 801 2$bOCLCQ 801 2$bOCLCF 801 2$bOCLCO 801 2$bGPO 906 $aBOOK 912 $a9910698454103321 996 $aCurrent issues in deposit insurance$93509264 997 $aUNINA LEADER 05281nam 22007695 450 001 9910298444303321 005 20200702002112.0 010 $a3-319-18144-0 024 7 $a10.1007/978-3-319-18144-8 035 $a(CKB)3710000000444474 035 $a(EBL)3567670 035 $a(SSID)ssj0001534427 035 $a(PQKBManifestationID)11892904 035 $a(PQKBTitleCode)TC0001534427 035 $a(PQKBWorkID)11494090 035 $a(PQKB)10802007 035 $a(DE-He213)978-3-319-18144-8 035 $a(MiAaPQ)EBC3567670 035 $a(PPN)187689725 035 $a(EXLCZ)993710000000444474 100 $a20150710d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aChemistry, Biochemistry and Pharmacology of Hydrogen Sulfide /$fedited by Philip K. Moore, Matt Whiteman 205 $a1st ed. 2015. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015. 215 $a1 online resource (384 p.) 225 1 $aHandbook of Experimental Pharmacology,$x0171-2004 ;$v230 300 $aDescription based upon print version of record. 311 $a3-319-18143-2 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aPart I Biochemistry, molecular biology and chemistry -- 1 H2Ssynthesizing enzymes: biochemistry and molecular aspects -- Part II Molecular mechanisms of action -- 2 Sulfhydration and H2S -- 3 Persulfide formation and H2S -- Part III Cardiovascular system -- 4 H2S and blood vessels - an overview -- 5 Hydrogen sulfide and urogenital tract -- 6 H2S - cardiac function and cardiac disease -- 7 H2S and platelets ? a possible role in thrombosis? -- Part IV Inflammation and inflammatory disease -- 8 H2S and inflammation  - an overview -- 9 H2S and neuroinflammation -- Part V H2S and the nervous system -- 10 Brain, learning and memory: role in neurodegenerative diseases -- 11 H2S and pain ? inflammatory and neuropathic -- Part VI H2S, angiogenesis and cancer -- 12 H2S and colon cancer -- 13 The role of H2S in cancer and tumor development -- Part VII H2S and ageing -- 14 H2S ? a new approach to lifespan enhancement and healthy aging? -- Part VIII H2S, measurement and possible therapeutics? -- 15 Measurement of H2S ? probes comes of age? -- 16 S-propargylcysteine ? a novel H2S donor with therapeutic potential -- 17 Mitochondria-targetted sulfide donors -- 18 Medicinal chemistry - insights into the development of novel H2S donors. 330 $aThis book puts hydrogen sulfide in context with other gaseous mediators such as nitric oxide and carbon monoxide, reviews the available mechanisms for its biosynthesis and describes its physiological and pathophysiological roles in a wide variety of disease states. Hydrogen sulfide has recently been discovered to be a naturally occurring gaseous mediator in the body. Over a relatively short period of time this evanescent gas has been revealed to play key roles in a range of physiological processes including control of blood vessel caliber and hence blood pressure and in the regulation of nerve function both in the brain and the periphery. Disorders concerning the biosynthesis or activity of hydrogen sulfide may also predispose the body to disease states such as inflammation, cardiovascular and neurological disorders. Interest in this novel gas has been high in recent years and many research groups worldwide have described its individual biological effects. Moreover, medicinal chemists are beginning to synthesize novel organic molecules that release this gas at defined rates with a view to exploiting these new compounds for therapeutic benefit. 410 0$aHandbook of Experimental Pharmacology,$x0171-2004 ;$v230 606 $aPharmacology 606 $aHuman physiology 606 $aNeurosciences 606 $aClinical biochemistry 606 $aPharmaceutical chemistry 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 606 $aHuman Physiology$3https://scigraph.springernature.com/ontologies/product-market-codes/B13004 606 $aNeurosciences$3https://scigraph.springernature.com/ontologies/product-market-codes/B18006 606 $aMedical Biochemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/H35005 606 $aMedicinal Chemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/C28000 615 0$aPharmacology. 615 0$aHuman physiology. 615 0$aNeurosciences. 615 0$aClinical biochemistry. 615 0$aPharmaceutical chemistry. 615 14$aPharmacology/Toxicology. 615 24$aHuman Physiology. 615 24$aNeurosciences. 615 24$aMedical Biochemistry. 615 24$aMedicinal Chemistry. 676 $a546.723 702 $aMoore$b Philip K$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aWhiteman$b Matt$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910298444303321 996 $aChemistry, Biochemistry and Pharmacology of Hydrogen Sulfide$92526661 997 $aUNINA